No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.
www.jubilantpharmova.comNo one on the platform currently holds JUBLPHARMA.BO.
No tracked institution reports a position in JUBLPHARMA.BO as of their last filing.
No one on the platform has traded JUBLPHARMA.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.6% | 3.4% | 15.1% | — | — | — |
| Rev. Growth % | 14.4% | 6.3% | ||||
| Profit Margin % | 4.8% | 4.7% | 7.7% | |||
| Free Cash Flow Margin % | -5.3% | -0.7% | 6.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $93.4B | +15.3% | $40.50 | $34.73–$46.27 | — | 2 |
| 2028 | $105.4B | +12.9% | $57.63 | $54.72–$60.53 | — | 2 |
| 2029 | $112.6B | +6.8% | $58.50 | $57.75–$59.25 | — | 1 |
| 2030 | $130.8B | +16.1% | $63.20 | $62.39–$64.01 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | $5.80 | $3.50 | -39.7% |
| 2026-05-22 | $7.45 | $7.80 | +4.7% |
| 2026-02-06 | $8.25 | $5.00 | -39.4% |
| 2025-10-31 | $6.85 | $7.80 | +13.9% |
| 2025-07-29 | $6.40 | $6.50 | +1.6% |
| 2025-05-16 | $8.50 | $9.75 | +14.7% |
| 2025-01-31 | $6.10 | $7.30 | +19.7% |
| 2024-10-25 | $4.90 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| JUBLPHARMA.BOJubilant Pharmova Limited | $1009.60 | -1.51% | $160.1B | — |
| APLLTD.BOAlembic Pharmaceuticals Limited | $822.40 | +1.47% | $161.6B | — |
| APLLTD.NSAlembic Pharmaceuticals Limited | $824.75 | +1.70% | $162.1B | — |
| CAPLIPOINT.NSCaplin Point Laboratories Limited | $2570.60 | -6.69% | $195.4B | — |
| ERIS.BOEris Lifesciences Limited |
| $7.10 |
| +44.9% |
| $1311.00 |
| -3.25% |
| $181.7B |
| — |
| ERIS.NSEris Lifesciences Limited | $1310.10 | -3.35% | $181.6B | — |
| GRANULES.BOGranules India Limited | $872.50 | -4.08% | $217.2B | — |
Source: Financial Modeling Prep · peers by sector/industry